Nitto Danko Corp., of Osaka, Japan, said it has launched a new start-up, Nitto Biopharma Inc., of San Diego, as of Jan. 11. Nitto Bio is to focus on drug discovery and development for diseases such as fibrosis. Nitto Danko’s anti-liver fibrosis drug, ND-L02-s0201, is in clinical trials in the U.S., Europe and Japan.